

17th St. & Constitution Avenue N.W. Washington, D.C. 20006 United States of America

Organization of American States

P. 202.458.3000 www.oas.org

FIFTY-EIGHTH REGULAR SESSION November 11 - 13, 2015 Trujillo, Perú

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION CICAD

Secretariat for Multidimensional Security

OEA/Ser.L/XIV.2.58 CICAD/doc.2226/15 12 November 2015 Original: Español

GROUP OF EXPERTS ON CHEMICAL SUBSTANCES AND PHARMACEUTICAL PRODUCTS

GROUP OF EXPERTS ON CHEMICAL SUBSTANCES AND PHARMACEUTICAL PRODUCTS



Meeting

• July 15 to 17, 2015

Quito, Ecuador



Participants

14 Member States:

Argentina Brazil Chile Costa Rica Guatemala Peru Venezuela Bolivia Canada Colombia Mexico Panama United States Uruguay

UNODC / PRELAC and SMART Program



1. The use of the products generated by the Group of Experts (ES/CICAD)

Brief study on the usefulness of the documents, guides, and tools produced by the Group of Experts; and on the extent to which the member states are making use of those products.



2. New approach to the preventive control of chemical substances (Ecuador)

The government of Ecuador reoriented its efforts to take into consideration the socioeconomic aspects of the drugs phenomenon, through a country approach that declares: A well-developed industry with state assistance reduces the risk of chemical substances being diverted for illicit purposes.



3. Legal and control options for dealing with new psychoactive substances (NPS) (United States)

Presentation analyzing the problems faced by state officials in identifying those substances and assessing the risks and threats they pose, in addition to the scant regional legislation on the topic.



4. Presentation by the National Scientific Reference Center for Narcotics and Psychotropic Substances of Ecuador (Ecuador)

General introduction to Ecuador's experience with the control of new psychoactive substances. The presentation focused on Ecuador's National Scientific Reference Center for Narcotics and Psychotropic Substances



5. Unscheduled chemical substances used to manufacture illegal drugs (Mexico)

 Presentation on Mexico's experience with controlling unscheduled chemicals and the dynamic nature of the drugs situation.



Global evaluation of synthetic drugs – 2015

 Amphetamine-type stimulants and new
 psychoactive substances (UNODC)

Examination of the problems that currently exist as regards synthetic drugs, and of the challenges posed by synthetic drugs and new psychoactive substances in Latin America.



7. Recommendations on the 2016-2020 Draft Plan of Action of the Hemispheric Drug Strategy as regards the control of chemical substances and pharmaceutical products (ES/CICAD)

• Brief presentation on the process foreseen for preparing the Plan of Action, and a broader debate on the approach to be adopted in preparing it.



8. Request for contributions made by the International Narcotics Control Board (INCB) on the control of chemical substances as well (ES/CICAD)

• Invitation for consultations, completion of questionnaire for CICAD to send suggestions to the INCB.



Discussions and Draft Documents

- 1. Best practices for controlling internal movements of chemical substances to prevent diversions (Argentina)
- 2. Guidance and self-assessment tool for new psychoactive substances (NPS) (United States)



Plan of Action Working Groups

- 1. Guide to best practices on alternative approaches to controlling NPS that the member states could consider (United States)
- 2. Updating the best practices directive for investigations involving chemical substances (Ecuador)



Conclusions and Recommendations



Approval of Documents:

 Best practices for controlling internal movements of chemical substances to prevent diversions

2. Guidance and self-assessment tool for new psychoactive substances (NPS)



Adoption of Decisions: • Approval of proposed activities and plan of action • Creation of the working groups • Preparation of documents

Authorization of the Group's meeting in 2016 (venue to be determined)



GROUP OF EXPERTS ON CHEMICAL SUBSTANCES AND PHARMACEUTICAL PRODUCTS

